Loading clinical trials...
Loading clinical trials...
Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma
Conditions
Interventions
Irinotecan
temozolomide
+2 more
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
June 12, 2017
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
July 2, 2025
NCT06674265
NCT02748135
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions